Table 5.
Use of criteria in guidelines | Totala, n (%) | |||
---|---|---|---|---|
Not used, n (%) | Used but not defined, n (%) | Used and defined, n (%) | ||
Criteria related to evidence | ||||
Susceptibility to bias of studies | 6 (43) | 0 | 8 (57)b | 14 (100) |
Quality of studies | 1 (7) | 9 (64) | 4 (29) | 14 (100) |
How precise results are | 13 (93) | 1 (7) | 0 | 14 (100) |
Heterogeneity of results | 8 (57) | 6 (43) | 0 | 14 (100) |
Criteria related to outcomes | ||||
Size of beneficial effect | 8 (57) | 6 (43) | 0 | 14 (100) |
Risks | 11 (79) | 2 (14) | 1 (7) | 14 (100) |
Costs | 12 (86) | 2 (14) | 0 | 14 (100) |
aThere was no scale for grading evidence or strength of recommendations in three guidelines
bThe best study designs were usually considered to be randomized clinical trials